Biodesix and Addario Lung Cancer Medical Institute initiate study to predict overall survival using checkpoint immunotherapy for lung cancer patients

Biodesix and Addario Lung Cancer Medical Institute initiate study to predict overall survival using checkpoint immunotherapy for lung cancer patients

BOULDER and SAN CARLOS, Calif. -- Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical... Read More

Tuesday September 1, 2020 0 comments Tags: Boulder, Biodesix, Addario Lung Cancer Medical Institute, Scott Hutton